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Abstract The prodrug capecitabine (Xeloda) has been an
important drug for treatment for gastrointestinal cancer
(GI-cancer). This study explores the efficacy of continuous
metronomic Xeloda, as well as tolerability and best
response during treatment. Patients (n = 35) with stage IV
GI-cancer were included in the study and were divided into
two groups; upper (n = 13) and lower (n = 22) GI-cancer.
All patients were given continuous metronomic Xeloda
(500 mg 9 2). Best response was measured by radiological
and clinical examination including laboratory results.
Standard RECIST criteria were used. Median age was 66
(range 29–86). Those patients who received first and sec-
ond line had the longest duration of treatment. For patients
with metastatic gastrointestinal cancer, metronomic cape-
citabine (Xeloda) may be beneficial both as far as tumor
control and quality of life is concerned. In this pilot study,
palliation for more than 2 years is observed for 6 of the 35
patients.
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Introduction
5-Fluorouracil (5-FU) has been the backbone of treatment
for gastrointestinal cancer (GI-cancer) since the discovery
of its efficacy in the fifties. In spite of the wide experience
in clinical oncology, there are still controversies regarding
the optimal administration of the drug. The latest devel-
opment with an oral administration of the prodrug cape-
citabine opened new possibilities in this matter [1]. In this
pilot study of patients with tumors in the GI tract, the
efficacy of continuous metronomic capecitabine was
explored. We investigated both the tolerability and the best
response to treatment.
Another goal with the study was to investigate whether
the drug was efficient in an elderly patient population given
in a continuously low-dose setting.
This was the only alternative to treat the patients since
the normal standard chemotherapy regimen was considered
too toxic. Here, patients with severe side effects from
conventional treatment were included.
Materials and methods
Study design and patients
This pilot study included 35 patients in stage IV (GI-can-
cer) with primary metastatic or recurrent disease planned
for treatment during 2010–2012. Patients were recruited
from one county in Sweden. Seventeen of the 35 patients
were more than 70 years of age, ranging from 29 to
86 years.
Many of the patients were pretreated with conventional
chemotherapy before treatment with low-dose capecitabine.
The group treated with metronomic capecitabine in the
first line was patients who were not considered suitable for
conventional treatment mostly because of high age or
medical contraindications. The group with this treatment in
second line was generally patients with severe side effects
after conventional chemotherapy.
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We divided the patients into two groups as shown in
Fig. 1; one group with upper GI-cancer and one with lower
GI-cancer.
The malignancies representing the upper GI-cancer were
carcinoma of the esophagus, the hepatobiliary system and
the pancreas. Malignancies representing the lower GI-
cancer were carcinoma of the colon and rectum.
The treatment with low-dose capecitabine (500 mg 9 2)
was considered for patient with a high age who received
toxicity grade III–IV to prior chemotherapy or because
evidence-based alternatives had already been tested.
The patients were followed every 4th week with clinical
examination and laboratory measurements in an outpatient
basis. Radiological examination with response evaluation
was done approximately after 2 months of treatment, and
RECIST criteria were used.
The patient data included the information of recurrent
disease, start of treatment with low-dose capecitabine, the
reason for treatment as well as duration of treatment. Other
anticancer drugs during study were noted and also other
malignancies present.
Since the follow-up was quite frequent, the best
response during the treatment for most patients could be
easily determined. End points used in this study were
progress, regress or stable disease as well as the cases
where no assessment of response was possible.
Results
Since the material is heterogeneous, we wish to illustrate
them by describing three individual cases as following.
The first patient received treatment with capecitabine
and bevacizumab as the fifth line of treatment (Nr 28) (see
Table 1) was a women born in 1973. She was diagnosed
with cecal cancer in 2003. There was a doctor delay of
more than a year, and when she finally was diagnosed, she
had metastatic disease. She lived with metastatic disease
for 9.5 years with intermittent chemotherapy and most of
the time with good quality of life (QoL). Shortly, before
her death, she participated in a horse show competition.
She received metronomic capecitabine and bevacizumab
for 2 years.
The second patient (NR 20) (Table 1) is a younger man
born in 1977. He was diagnosed in 2010 with cancer of the
hepatobiliary system and lung metastases. He started with
conventional chemotherapy with severe side effects after
two cycles. He was motivated for treatment but not phys-
ically fit which was the incitement to switch to metronomic
capecitabine. A partial regression (PR) was observed.
Radiofrequency (RF) treatment was given to a complete
response in the liver in October 2012. He has shown stable
disease by now for more than 2 years in the lungs being
able to work full time and is alive and well.
The third patient receiving metronomic capecitabine
(NR 21) (see Table 1) is a man with adenocarcinoma
diagnosed with a liver biopsy at the age of 86 years. When
diagnosed, the multidisciplinary team conference hesitated
to give him treatment. While still motivated for treatment,
he made sure to be accepted for doctors’ appointment at the
oncology department. Treatment was started with metro-
nomic capecitabine and was well tolerated without any side
effects. Three months later, radiology confirmed regress of
the disease, however, not a PR. He had stable disease for
1 year. Because of progress, he is now without tumor-
specific treatment and has lived 2 years with good QoL and
no side effects of treatment. Since his response to the
treatment was good, he was reconsidered for local treat-
ment. Because of the location of the tumor nearby big
vessels, RF treatment was not an alternative. He was
offered stereotactic treatment but declined when he was
informed of possible side effects. He is alive and well.
Within the group selected for this treatment because of
unacceptable toxicity grade III–IV (13 patients), only 3 of
them were 75 years or older.
In the group with upper GI-cancer, about 30 % (n = 4)
showed regress of disease (PR), 23 % (n = 3) progress and
46 % (n = 6) stable disease. In the group with lower GI-
cancer, about 61 % (n = 11) showed progress and 39 %
(n = 7) stable disease.
Figure 2 shows best response divided between men and
women, and Fig. 3 shows the duration of treatment for both
men and women in the two groups. Obviously, treatment
duration was longer for upper GI-cancer. Still, the median
duration of treatment was quite long for both groups. As
shown in Fig. 3, one patient with the duration of treatment
of 822 days was the young woman described above (NR
28). The other two dots present other two patients with an
exceptional long duration of treatment.
Fig. 1 The number of patients in the two groups with upper and
lower GI-cancer
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Discussion
The number of people diagnosed with cancer is increasing
in Sweden. One of the reasons is thought to be an
increasing healthy elderly population.
A woman of 65 years old has a life expectancy of
20 years more and man about 18 years. About 60 % of the
patients diagnosed with cancer are 65 year or older. Still,
they are rarely included in research studies regarding new
methods or treatments. Studies from USA as well as
Sweden show that there are a great number of older
patients not receiving any antitumor treatment at all [2].
The reason is not yet established but might be the lack of
information of proven therapies as well as resignation.
Colorectal cancer is the third most common diagnosis
among both men and women in Sweden. There are
approximately 5,000 new cases of colorectal cancer diag-
nosed every year. Almost half of those are over 75 years
old.
The incidence increases with increasing age and doubles
every seventh years for patients over 50 years of age. There
is a lack of information about the optimal treatment
regarding efficacy as well as QoL in patients suffering from
CRC over 70 years of age, who often suffer from other
diseases as well. Within the palliative setting, it is impor-
tant to try to prevent disease progression without com-
promising patients QoL more than necessary. A continuous
low-dose approach is not commonly used for patients with
gastrointestinal cancer; however, earlier reports have been
done both for esophageal cancer, breast cancer and pros-
tatic cancer [3]. The patients within this report were those
with very severe side effects with conventional treatment
and patients with an old age where the clinician hesitated to
offer conventional toxic treatment. Moreover, a group of
patients were palliated during a long period where the
conventional treatment regimes all have been explored.
Of these 35 patients, six are still alive more than
24 months after initiation of treatment, all with active
disease but stable disease and good QoL. Of these six, two
had mucous adenocarcinoma, which we know is often
therapy resistant, three patients had cholangiocarcinoma
and one had adenocarcinoma in the liver.
Age is measured chronologically in many circum-
stances. From a medical perspective, the chronological age
is more irrelevant as the patient becomes older. In a group
of 80 years old, you can find healthy physically active
people, and persons with many diseases who require a lot
of care and help. Differences in treatment can be motivated
but sometimes motivations for the differences are not fully
explained other than the chronological age of the patient.
With the help of magnetic resonance imaging (MRI) and
computed tomography (CT), we can study the affected
organ/organs with accuracy. The disadvantage of this is
also that we receive more information than we would like,
as we can notice other pathologies not symptomatic for the
patient. Since this is seen especially in older patients,
examination with MRI or CT is excluded in many cases
even though metastases will not be found. This is not
acceptable, and neither is the fact that many older patients
are excluded from multidisciplinary conferences.
The relative 5-year survival for all cancer diagnoses
today is 67%, and 36 % in the beginning of the 70s indi-
cating that the prognosis for cancer patients has improved
tremendously [4].
It is important to give optimal treatment to patients with
colorectal cancer. However, there is a lack of information
on treatment efficiency and safety for CRC in the oldest to
old patients often suffering from underlying comorbidity.
Lack of precise knowledge may also influence an option of
providing a palliative care only [5, 6].
Our study shows that for the patient with toxicity to
conventional chemotherapy or old age, metronomic cape-
citabine (Xeloda) can serve as an alternative treatment.
Both tumor regression and SD were observed.
Fig. 2 Best response in both groups
Fig. 3 Duration of treatment
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This study could be the incitement for a future ran-
domized prospective study among the elderly patient
group. A proper patient group would be patients with an
age of 75 years or older with metastatic CRC disease, an
ECOG performance status of 0–1 with acceptable hema-
tological, liver and renal function tests. Results from such a
study will fill a huge knowledge gap benefitting the
emerging elderly population with CRC.
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